Lakefront Biotherapeutics NV (LON:0JXZ)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 1.58B +1.7% |
| Revenue (ttm) | 852.96M +259.4% |
| Net Income | 513.75M |
| EPS | 7.57 |
| Shares Out | n/a |
| PE Ratio | 3.27 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,921 |
| Open | 29.88 |
| Previous Close | 29.87 |
| Day's Range | 29.18 - 29.90 |
| 52-Week Range | 22.38 - 30.65 |
| Beta | 0.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About LON:0JXZ
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps... [Read more]
Financial Performance
In 2025, LON:0JXZ's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.
Financial numbers in EUR Financial StatementsNews
Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London
Mechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthca...
Galapagos NV Announces Gamgertamig Preliminary Phase 1b Data and Poster Presentation at 2026 ASH Meeting
Galapagos NV announced the acceptance of a poster presentation at the 2026 American Society of Hematology Annual Meeting, scheduled for December 12-15, featuring preliminary data for gamgertamig in re...
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent ...
Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors
Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board
Lakefront sells early-stage cell therapy pipeline to Armed Cell for $8M upfront
Lakefront Biotherapeutics (LKFT) announced that it has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology company developing next-...
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
Previously announced wind-down of the legacy cell therapy activities is substantially complete Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ...
Acquisition of Own Shares
Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (...
Lakefront upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Lakefront Biotherapeutics (LKFT) to Outperform from Sector Perform with a price target of $45, up from $26. The firm sees a “meaningful opportunity” for gamgertamig in rare…
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
Lakefront Biotherapeutics American Depositary Shares NASDAQ: LKFT said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of i...
Lakefront Biotherapeutics NV Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has undergone a major transformation, focusing on T-cell engagers and securing gamgertamig as a lead asset with Gilead as a key partner. Registration studies in autoimmune diseases are set for next year, supported by strong financials and a robust pipeline. Regulatory and industry trends are favorable.
Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Mechelen, Belgium; 8 September 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the Morgan Stanley 24th Annual Glob...
Lakefront Biotherapeutics granted orphan drug designation for gamgertamig
Lakefront Biotherapeutic (LKFT) announced that the FDA has granted orphan drug designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan ...
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has grante...
Lakefront Receives Transparency Notification from Bank of America
Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley
Morgan Stanley analyst Judah Frommer lowered the firm’s price target on Lakefront Biotherapeutics (LKFT) to $26 from $30 and keeps an Equal Weight rating on the shares. The firm updated…
Lakefront Biotherapeutics NV Earnings release: Q2 2026
Lakefront Biotherapeutics NV released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Lakefront Biotherapeutics NV Quarterly report: Q2 2026
Lakefront Biotherapeutics NV has published its Q2 2026 quarterly earnings report on August 11, 2026.
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research ...
Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley
Morgan Stanley resumed coverage of Lakefront Biotherapeutics (LKFT) with an Equal Weight rating and $30 price target after the recent closing of the Ouro Medicines acquisition. The acquisition of Ouro...
Lakefront Receives Transparency Notification from Madison Avenue Partners
Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners.
Lakefront Biotherapeutics announces EUR 50M share repurchase program
Lakefront Biotherapeutics (LKFT) announced the launch of a share repurchase program, under which the company may repurchase ordinary shares for an aggregate amount of up to EUR 50M. Repurchases under…
Lakefront Announces Initiation of €50 Million Stock Repurchase Program
Mechelen, Belgium ; June 9, 2026, 22:01 CET; regulated information – Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), u...
Lakefront Biotherapeutics appoints Eric Hedrick chief medical officer
Lakefront Biotherapeutics (LKFT) announced that Eric Hedrick has been appointed chief medical officer. Hedrick report to Henry Gosebruch, CEO and join the company’s management committee. Prior to join...
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
Mechelen, Belgium ; June 8, 2026, 22:01 CET; Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leade...